In human prostate cancer, the combination of paclitaxel and metformin suppressed proliferation and induced apoptosis via ROS, promoting expression of the pro-apoptotic protein p53, and inducing mitochondrial damage (Zhao et al., 2019). The gene discussed is TP53; the disease is prostate carcinoma.